1. Home
  2. MIST vs EYEN Comparison

MIST vs EYEN Comparison

Compare MIST & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • EYEN
  • Stock Information
  • Founded
  • MIST 2003
  • EYEN 2014
  • Country
  • MIST Canada
  • EYEN United States
  • Employees
  • MIST N/A
  • EYEN N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • EYEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MIST Health Care
  • EYEN Health Care
  • Exchange
  • MIST Nasdaq
  • EYEN Nasdaq
  • Market Cap
  • MIST 81.5M
  • EYEN 38.2M
  • IPO Year
  • MIST N/A
  • EYEN 2018
  • Fundamental
  • Price
  • MIST $1.43
  • EYEN $0.55
  • Analyst Decision
  • MIST Strong Buy
  • EYEN Strong Buy
  • Analyst Count
  • MIST 3
  • EYEN 2
  • Target Price
  • MIST $13.00
  • EYEN $12.00
  • AVG Volume (30 Days)
  • MIST 177.8K
  • EYEN 879.0K
  • Earning Date
  • MIST 11-11-2024
  • EYEN 11-11-2024
  • Dividend Yield
  • MIST N/A
  • EYEN N/A
  • EPS Growth
  • MIST N/A
  • EYEN N/A
  • EPS
  • MIST N/A
  • EYEN N/A
  • Revenue
  • MIST N/A
  • EYEN $31,405.00
  • Revenue This Year
  • MIST N/A
  • EYEN $50,309.30
  • Revenue Next Year
  • MIST N/A
  • EYEN $421.63
  • P/E Ratio
  • MIST N/A
  • EYEN N/A
  • Revenue Growth
  • MIST N/A
  • EYEN N/A
  • 52 Week Low
  • MIST $1.12
  • EYEN $0.37
  • 52 Week High
  • MIST $3.52
  • EYEN $2.57
  • Technical
  • Relative Strength Index (RSI)
  • MIST 42.50
  • EYEN 52.60
  • Support Level
  • MIST $1.41
  • EYEN $0.52
  • Resistance Level
  • MIST $1.53
  • EYEN $0.59
  • Average True Range (ATR)
  • MIST 0.07
  • EYEN 0.05
  • MACD
  • MIST -0.01
  • EYEN 0.01
  • Stochastic Oscillator
  • MIST 26.96
  • EYEN 66.45

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About EYEN Eyenovia Inc.

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Share on Social Networks: